- Home
- IMOS vs KLRA Comparison
IMOS vs KLRA Comparison
Compare IMOS & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMOS | KLRA |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2007 | 2026 |
Fundamental Metrics
Financial Performance| Metric | IMOS | KLRA |
|---|---|---|
| Price | $57.27 | $16.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 69.7K | ★ 587.4K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.75 | N/A |
| Revenue Next Year | $4.21 | N/A |
| P/E Ratio | $158.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.33 | $15.15 |
| 52 Week High | $78.35 | $23.82 |
Technical Indicators
Market Signals| Indicator | IMOS | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 44.63 |
| Support Level | $55.07 | $16.74 |
| Resistance Level | $60.67 | $19.02 |
| Average True Range (ATR) | 1.79 | 1.30 |
| MACD | 0.45 | -0.08 |
| Stochastic Oscillator | 74.21 | 43.15 |
Price Performance
Historical ComparisonAbout IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About KLRA Kailera Therapeutics Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.